Get the Daily Brief
Latest Biotech News
OpenAI rolls ChatGPT into hospitals — asks for health data
OpenAI launched ChatGPT for Healthcare, a product that expands the company’s footprint into hospitals and health systems by offering a dedicated, clinician-facing workflow for health conversations...
Alveus raises $160M to chase MariTide-like obesity program
Alveus Therapeutics launched with about $160 million in Series A funding to advance a Phase‑2 ready dual-agonist obesity candidate that targets the same two pathways as Amgen’s MariTide, while...
CBS: Stem cell route to helper T cells could enable off‑the‑shelf cell therapies
Researchers at the University of British Columbia reported a reproducible method to produce human helper (CD4+) T cells from pluripotent stem cells, a longstanding manufacturing bottleneck for...
Storm Therapeutics partners with AlidaBio to track m6A changes in METTL3 trials
Storm Therapeutics announced a strategic collaboration with Alida Biosciences to use AlidaBio’s EpiPlex/EpiScout platforms to quantify transcript‑specific m6A RNA modifications in clinical samples...
Lilly snaps up Ventyx – $1.2B buy expands oral inflammation arsenal
Eli Lilly agreed to acquire San Diego biotech Ventyx Biosciences for roughly $1.2 billion in cash, targeting Ventyx’s clinical-stage NLRP3 inhibitor programs. Lilly said the buy adds oral NLRP3...
Parabilis raises $305M – VC vote for 'undruggable' protein strategy
Parabilis Medicines closed a $305 million Series F to accelerate development of its Helicon peptide platform and lead candidate zolucatetide, which targets intracellular beta‑catenin pathways. The...
EpiBiologics nets $107M – protein degraders draw Big Pharma backers
EpiBiologics raised $107 million in a Series B co-led by GV and J&J’s venture arm to advance its surface protein-targeting degraders (EpiTACs) toward human testing in lung and head-and-neck...
Vizgen raises $48M – spatial biology tools race heats up
Spatial transcriptomics company Vizgen closed a $48 million financing led by Arch Venture Partners, M Ventures and Northpond to accelerate commercial growth and push toward profitability. CEO Rob...
Guardant’s Shield wins Tricare coverage – screening goes military-wide
Guardant Health secured Tricare coverage for Shield, its blood-based colorectal cancer screening test, making the FDA‑cleared assay available with no copay to active-duty service members and...
Storm Therapeutics partners with Alida – m6A biomarkers hit the clinic
Storm Therapeutics announced a strategic partnership with Alida Biosciences to analyze transcript‑specific m6A RNA modifications in clinical samples from patients treated with Storm’s METTL3...
GSK, Ionis report Phase 3 wins — bepirovirsen poised for regulatory push
GSK and Ionis announced positive topline results from pivotal B‑Well 1 and B‑Well 2 Phase 3 studies of bepirovirsen, an antisense oligonucleotide for chronic hepatitis B that aims for a functional...
Gordian and Pfizer team up – in vivo screens seek obesity targets
Gordian Bio entered a collaboration with Pfizer to deploy Gordian’s in vivo mosaic screening platform in visceral adipose tissue to discover and prioritize obesity targets directly in...
Immuneering’s pancreatic pill posts survival edge – pivotal plans loom
Immuneering reported updated Phase 2a results for the MEK inhibitor atebimetinib combined with modified chemotherapy in first‑line pancreatic cancer, showing a 64% one‑year overall survival rate...
FDA cuts didn’t derail review clocks – staff kept drug timetables intact
An analysis found that despite extensive staff departures and leadership turnover at the FDA in 2025, reviewers largely met their user‑fee timelines for new drug reviews. Agency line staff...
Lilly buys Ventyx for $1.2B – bolsters oral NLRP3 pipeline
Eli Lilly agreed to acquire Ventyx Biosciences for about $1.2 billion to secure clinical-stage NLRP3 inhibitors and expand its inflammation and neurodegeneration portfolio. Lilly said the deal...
Parabilis raises $305M — pushes corkscrew peptides toward late‑stage testing
Parabilis Medicines closed a $305 million Series F to advance its Helicon peptide platform and lead candidate zolucatetide into later‑stage testing for oncology. The round, led by RA Capital,...
EpiBiologics nets $107M — prepares EPI‑326 for first‑in‑human studies
EpiBiologics announced a $107 million Series B to advance its extracellular protein degradation platform and its lead bispecific degrader, EPI‑326, toward clinical testing. The round was led by GV...
Alumis’ TYK2 pill tops Phase III — envudeucitinib stakes psoriasis claim
Alumis reported positive Phase III Onward1 and Onward2 results for its oral TYK2 inhibitor envudeucitinib in psoriasis, data that position the pill among leading oral therapies for the disease....
Immuneering’s pancreatic pill posts 64% one‑year survival — pivotal next
Immuneering reported updated Phase 2a data showing a 64% overall survival rate at 12 months for atebimetinib combined with modified chemotherapy in first‑line pancreatic cancer—well above...
GSK and Ionis claim Phase III wins for bepirovirsen — filings planned
GSK and partner Ionis announced positive topline results from two pivotal Phase III trials (B‑Well 1 and B‑Well 2) of bepirovirsen, an antisense oligonucleotide designed to deliver a functional...